|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessment of hormonal receptor immunoexpression and Her2 status in invasive breast cancer after conservative and radical surgery.
|
30534815 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, HER-2-positive expression and high Ki-67 expression are predictors of LVI, whereas the expression of ER, PR, CK5/6, EGFR, VEGF, E-cadherin, BCL11A and P53 is not associated with LVI in invasive breast cancer.
|
29416785 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The contest data set comprised digitized whole slide images (WSI) of sections from 86 cases of invasive breast carcinoma stained with both haematoxylin and eosin (H&E) and IHC for HER2.
|
28771788 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Postmenopausal women with histologically proven ER+ve, HER2-ve invasive breast cancer, 2 cm or greater, were enrolled in an open-label, single-arm study.
|
29158285 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HER2 over-expression is related with a poor prognosis in patients with invasive breast cancer tumors.
|
29970031 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multicolor immunohistochemical multiplex assays simultaneously demonstrating PD1, PD-L1, and CD8 or PD-L1, CD3, and CD163 were performed on tissue microarrays (TMA) representing 216 pretreatment cases of HER2-positive invasive breast carcinoma.
|
30230111 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fifteen patients with HER2 equivocal invasive breast cancer had Oncotype DX performed.
|
29498449 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The areas under the receiver operating curve of HER-2, Ki67, tumor size, and the combination of the 3 clinicopathological factors were 0.614 [P = .001, 95% confidence interval (CI): 0.544-0.683], 0.596 (P = .006, 95% CI: 0.529-0.662), 0.575 (P = .03, 95% CI: 0.510-0.641), and 0.670 (P < .001, 95% CI: 0.607-0.734), respectively.HER-2 positive expression, Ki67 high expression, and tumor size >2 cm were risk factors of LVI, whereas the power of the prediction model of LVI based on the 3 clinicopathological factors in invasive breast cancer was low.
|
30412123 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to increase pathologic complete response (pCR) in patients with invasive breast cancer by adding preoperative capecitabine to docetaxel following 5-fluorouracil, epirubicin, cyclophosphamide (FEC) (with trastuzumab for patients with HER2-positive disease) and to evaluate 5-year disease-free survival (DFS) associated with this preoperative regimen.
|
29582557 |
2018 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
|
28886093 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The discrepant prevalence of HER2 amplification among breast cancer subgroups indirectly suggests that HER2 may not play a crucial role in the transition of in situ to invasive breast cancer.
|
28567637 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Eight hundred women with HER2-negative early invasive breast cancer were recruited.
|
28548129 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inpatients with HER2 positive invasive breast cancer from 13 hospitals in Eastern China (2010-2015, <i>n</i> = 1,139) were included in this study.
|
28798274 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Her2/neu statuses of 369 consecutive cases of invasive breast cancer (from 351 patients) were assessed in a dual-testing algorithm that uses both IHC and fluorescence ISH (FISH).
|
28340220 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 testing of invasive breast cancer by in-situ hybridization guides therapy decisions.
|
28502100 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
|
28521178 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
42 randomly selected invasive breast cancer specimens were enumerated by fluorescence in situ hybridization (FISH)for HER2 and CEP17 markers using the Vysis HER2 assay (AbbotLaboratory, North Chicago, IL).
|
27417320 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.
|
28752841 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, we found that elevated CEP17 count can serve as a prognostic marker in luminal/HER2-negative subtype of invasive breast cancer.
|
27989787 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, the RT-qPCR assay is highly concordant (94%) with the continuous variable HER2 QIF assay, and may better reflect the true continuum of HER2 receptor status in invasive breast cancer.
|
28892092 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this research was to analyze the co-expression of P-glycoprotein and the markers of tissue hypoxia HIF-1α, EPO, and EPO-R by immunohistochemistry in invasive breast cancer classified according to the presence of steroid receptors and the HER2 receptors.
|
29181060 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 886 consecutive cases of primary invasive breast cancer conducted with dual-probe HER2 FISH testing between November 2013 and December 2015 were reviewed.
|
28861637 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The 21-gene recurrence score (RS) assay predicts response to adjuvant chemotherapy in patients with early-stage, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer, but to the authors' knowledge, the role of the assay in guiding the selection of chemotherapy regimen has not been established.
|
27787892 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessment of HER2 ITH was performed on whole tissue sections of pre-treatment samples from a cohort of 64 invasive breast carcinoma cases originally considered positive for HER2 and treated with anti-HER2 neoadjuvant chemotherapy.
|
28799059 |
2017 |
|
Invasive carcinoma of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
|
28457730 |
2017 |